iSpecimen
Woburn, Massachusetts, United States · Biotechnology, E Commerce, Healthcare
iSpecimen (Nasdaq: ISPC) offers an online marketplace for human biospecimens, connecting scientists in commercial and non-profit organizations with healthcare providers that have access to patients and specimens needed for medical discovery. Proprietary, cloud-based technology enables scientists to intuitively search for specimens and patients across a federated partner network of hospitals, labs,
Key facts
- Headquarters
- Woburn, Massachusetts, United States
- Employees
- Unknown
- Industries
- Biotechnology, E Commerce, Healthcare
- Status
- Public (ISPC)
- Website
- ispecimen.com
- Company page
Recent activity at iSpecimen
- : SEC 8-K (5.07): On October 9, 2026, iSpecimen Inc. held a special meeting of stockholders, where important proposals were voted upon by its shareholders. The meeting had a quorum with 1,287,547 shares represented, which is approximately 51.1% of the outstanding shares as of the record date of August 12, 2026. The outcome of the votes for Proposal Nos. 1, 3, 4, and 5 was documented, although the meeting was later adjourned regarding certain matters. This event reflects ongoing governance activities within the company and its commitment to shareholder engagement.
- : SEC 8-K (3.01): On September 8, 2026, iSpecimen Inc. received a Deficiency Letter from Nasdaq regarding non-compliance with Listing Rule 5550(b), which requires listed companies to maintain either $2.5 million in stockholders’ equity or $35 million in market value of listed securities. The Company was initially notified of this non-compliance on May 29, 2026, and has since submitted compliance plans on July 13, August 6, and September 4, 2026, outlining its strategies to remedy the issue. The extension granted to the Company indicates that it is working towards meeting the required standards, which is critical for its continued listing on Nasdaq. The financial implications of non-compliance could significantly affect investor confidence and market perception.
- : SEC 8-K (1.01): On September 4, 2026, iSpecimen Inc. entered into a Material Definitive Agreement through an Asset Purchase Agreement with Foldlab AI Ltd. The Company will acquire artificial intelligence assets for a total purchase price of $4,500,000, consisting of $2,000,000 in cash and $2,500,000 in shares of Common Stock. The cash portion includes a $750,000 payment at closing and two milestone payments of $625,000 each based on successful product delivery and acceptance. The Stock Consideration will be subject to a five-year escrow and lock-up period, preventing any transfer or sale of shares during that time. This acquisition enhances iSpecimen's technological capabilities in AI for health-related applications, positioning the Company strategically in the innovation sector.
- : iSpecimen Inc. Appoints Shahin Behroyan as New CEO
- : SEC 8-K (5.02): On August 26, 2026, Katharyn Field informed the Board of Directors of iSpecimen Inc. about her decision to transition from her role as Chief Executive Officer. Her departure was confirmed to be without any disagreements regarding the Company's operations or policies. Concurrently, the Board appointed Shahin Behroyan as the new Chief Executive Officer, effective immediately. This leadership transition is significant as it reflects a strategic change in management, with Mr. Behroyan bringing over two decades of experience, which could influence the Company's future direction and operations.
- : SEC 8-K (1.01): On August 12, 2026, iSpecimen Inc. entered into a Consulting Agreement with IR Agency LLC to provide marketing and advertising services aimed at communicating information about the Company to the financial community. The agreement spans a three-month term and involves a fee of $2,000,000, payable by August 13, 2026. The Consultant will issue up to ten news releases during this period and can terminate the agreement at any time. Key provisions include non-refundability of the fee upon termination and adherence to U.S. securities laws, addressing both companies' obligations and liabilities throughout the term of the consulting services.
- : SEC 8-K (1.01):
- : SEC 8-K (1.01): On August 5, 2026, iSpecimen Inc. entered into a Placement Agency Agreement with E.F. Hutton & Co. and a Securities Purchase Agreement with investors to issue 996,231 shares of common stock and pre-funded warrants to purchase up to 2,849,923 additional shares for an aggregate price of $5,000,000. The offering closed on August 7, 2026, and the proceeds will be used for repaying liabilities, potential acquisitions, and working capital. The Placement Agent received a 4.0% fee on the gross proceeds of the offering. The agreements contain standard representations, warranties, and obligations for the parties involved.
- : SEC 8-K (8.01):
- : iSpecimen
iSpecimen funding history
| Date | Round | Amount |
|---|---|---|
| May 2026 | Post-IPO Equity | $5.0M |
| Dec 2025 | Series C | $5.5M |
| Aug 2025 | Seed | $1.8M |
| Dec 2021 | Venture | $21.0M |
| Aug 2018 | Venture | $800K |
Leadership
- Mackenzie Anderson, Director, Key Accounts
- Christopher Ianelli, Executive Officer, Director
- Andrew Ross, Director
- George Scholl, Director
- Jill Mullan, Executive Officer, Director
- Steven Gullans, Director
- John III, Director
- Margaret Lawrence, Director
- Jill Mullan, Director
- George Scholl, Director
- Andrew Ross, Director
- Christopher Ianelli, Executive Officer, Director
Verified email and direct lines for iSpecimen’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Employee benefit plans
iSpecimen files 2 employee benefit plans with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
iSpecimen in the news
- iSpecimen Inc. Announces Pricing of $5 Million Public Offering of Common Stock and Pre-Funded Warrants - Yahoo Finance (Aug 06, 2026)
- iSpecimen Supports Hospital Validation of New Chemistry Analyzer - Yahoo Finance (Sep 29, 2026)
- iSpecimen Completes Large-Scale International Cancer Research Order; Samples Shipped Within Three Weeks - Yahoo Finance (Aug 20, 2026)
- Scientists just looked inside Darwin’s 200-year-old specimen jars without opening them - Science Daily (Mar 05, 2026)
- Haystack MRD® Demonstrates Robust Clinical Performance in Specimen Cohort from the Landmark DYNAMIC Colorectal Cancer Trials - PR Newswire (Oct 01, 2026)
- Kyawthuite is Earth’s rarest mineral — only one specimen has ever been found - The Brighter Side of News (Jun 21, 2026)
- Personalis Enables Global Biopharma Support with CE-IVD Marked Specimen Collection Kits - Business Wire (Jun 09, 2026)
- iSpecimen Announces 1-for-40 Reverse Stock Split - Yahoo Finance (Apr 24, 2026)
Companies similar to iSpecimen
- ReCode Therapeutics · Biotechnology, Healthcare, Health Care
- Oruka Therapeutics · Biotechnology, Healthcare, Health Care
- Avalon Globocare Corp. · Biotechnology, Healthcare, Health Care
- Beam Therapeutics Inc. · Biotechnology, Healthcare, Health Care
- Olema Pharmaceuticals, Inc. · Biotechnology, Healthcare, Health Care
About iSpecimen: questions and answers
What does iSpecimen do?
iSpecimen (Nasdaq: ISPC) offers an online marketplace for human biospecimens, connecting scientists in commercial and non-profit organizations with healthcare providers that have access to patients and specimens needed for medical discovery. Proprietary, cloud-based technology enables scientists to intuitively search for specimens and patients across a federated partner network of hospitals, labs,
Where is iSpecimen headquartered?
iSpecimen is headquartered in Woburn, Massachusetts, United States.
Has iSpecimen raised funding?
Yes. Fundz has recorded 5 funding events for iSpecimen. The most recent, Post-IPO Equity of $5.0M, was in May 2026.
What is the latest news on iSpecimen?
On Oct 09, 2026, SEC 8-K (5.07): On October 9, 2026, iSpecimen Inc. held a special meeting of stockholders, where important proposals were voted upon by its shareholders. The meeting had a quorum with 1,287,547 shares represented, which is approximately 51.1% of the outstanding shares as of the record date of August
Is iSpecimen a public company?
Yes. iSpecimen is publicly traded under the ticker ISPC.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy